Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
Foghorn Therapeutics (NASDAQ: FHTX), a clinical-stage biotech company, announces its participation in three major investor conferences. The company, which focuses on developing medicines targeting abnormal gene expression through its Gene Traffic Control® platform, will present at:
- Jefferies London Healthcare Conference on November 19, 2024 (11:30 AM GMT)
- 7th Annual Evercore HealthCONx Conference on December 3, 2024 (1:20 PM EST)
- Citi Global Healthcare Conference on December 4, 2024
CEO Adrian Gottschalk will lead fireside chats at Jefferies and Evercore events, with one-on-one meetings scheduled at all three conferences. Webcasts will be available on the company's website for 30 days.
Foghorn Therapeutics (NASDAQ: FHTX), una azienda biotech in fase clinica, annuncia la sua partecipazione a tre importanti conferenze per investitori. L'azienda, che si concentra sullo sviluppo di farmaci mirati all'espressione genica anormale attraverso la sua piattaforma Gene Traffic Control®, presenterà:
- Jefferies London Healthcare Conference il 19 novembre 2024 (11:30 AM GMT)
- 7th Annual Evercore HealthCONx Conference il 3 dicembre 2024 (1:20 PM EST)
- Citi Global Healthcare Conference il 4 dicembre 2024
Il CEO Adrian Gottschalk condurrà discussioni informali negli eventi di Jefferies e Evercore, con incontri one-to-one programmati in tutte e tre le conferenze. I webcast saranno disponibili sul sito web dell'azienda per 30 giorni.
Foghorn Therapeutics (NASDAQ: FHTX), una empresa biotecnológica en etapa clínica, anuncia su participación en tres importantes conferencias para inversores. La empresa, que se centra en desarrollar medicamentos que apunten a la expresión genética anormal a través de su plataforma Gene Traffic Control®, presentará:
- Jefferies London Healthcare Conference el 19 de noviembre de 2024 (11:30 AM GMT)
- 7th Annual Evercore HealthCONx Conference el 3 de diciembre de 2024 (1:20 PM EST)
- Citi Global Healthcare Conference el 4 de diciembre de 2024
El CEO Adrian Gottschalk liderará charlas informales en los eventos de Jefferies y Evercore, con reuniones uno a uno programadas en las tres conferencias. Las retransmisiones web estarán disponibles en el sitio web de la empresa durante 30 días.
Foghorn Therapeutics (NASDAQ: FHTX), 임상 단계의 생명공학 회사는 세 가지 주요 투자자 회의에 참여한다는 발표를 하였습니다. 이 회사는 Gene Traffic Control® 플랫폼을 통해 비정상적인 유전자 발현을 목표로 하는 의약품 개발에 중점을 두고 있으며, 다음과 같은 회의에 발표할 예정입니다:
- Jefferies London Healthcare Conference 2024년 11월 19일 (오전 11시 30분 GMT)
- 7th Annual Evercore HealthCONx Conference 2024년 12월 3일 (오후 1시 20분 EST)
- Citi Global Healthcare Conference 2024년 12월 4일
CEO 아드리안 고트샬크가 Jefferies와 Evercore 이벤트에서 대담을 이끌고, 세 회의 모두에서 일대일 미팅이 예정되어 있습니다. 웹캐스트는 회사의 웹사이트에서 30일 동안 이용할 수 있습니다.
Foghorn Therapeutics (NASDAQ: FHTX), une entreprise biopharmaceutique en phase clinique, annonce sa participation à trois grandes conférences pour investisseurs. L'entreprise, qui se concentre sur le développement de médicaments ciblant l'expression génique anormale grâce à sa plateforme Gene Traffic Control®, présentera :
- Jefferies London Healthcare Conference le 19 novembre 2024 (11h30 GMT)
- 7th Annual Evercore HealthCONx Conference le 3 décembre 2024 (13h20 EST)
- Citi Global Healthcare Conference le 4 décembre 2024
Le PDG Adrian Gottschalk animera des discussions informelles lors des événements Jefferies et Evercore, avec des réunions individuelles programmées lors des trois conférences. Les webcasts seront disponibles sur le site de l'entreprise pendant 30 jours.
Foghorn Therapeutics (NASDAQ: FHTX), ein biotechnologisches Unternehmen in der klinischen Phase, gibt seine Teilnahme an drei bedeutenden Investorenkonferenzen bekannt. Das Unternehmen, das sich auf die Entwicklung von Medikamenten zur gezielten Beeinflussung der abnormen Genexpression durch seine Gene Traffic Control®-Plattform konzentriert, wird auf folgenden Veranstaltungen präsentieren:
- Jefferies London Healthcare Conference am 19. November 2024 (11:30 Uhr GMT)
- 7th Annual Evercore HealthCONx Conference am 3. Dezember 2024 (13:20 Uhr EST)
- Citi Global Healthcare Conference am 4. Dezember 2024
CEO Adrian Gottschalk wird in den Gesprächen bei den Jefferies- und Evercore-Veranstaltungen leiten, wobei in allen drei Konferenzen Einzelgespräche geplant sind. Webcasts werden für 30 Tage auf der Unternehmenswebsite verfügbar sein.
- None.
- None.
CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced management's participation in the Jefferies London Healthcare Conference, the 7th Annual Evercore HealthCONx Conference, and the Citi Global Healthcare Conference. With an initial focus in oncology, Foghorn’s Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.
Jefferies London Healthcare Conference
- Fireside Chat: Tuesday, November 19, 2024, at 11:30 a.m. GMT in London, UK
- Foghorn Presenter: Adrian Gottschalk, President and Chief Executive Officer
- Please find a link to the webcast here
- Management will also participate in one-on-one meetings on Tuesday, November 19
7th Annual Evercore HealthCONx Conference
- Fireside Chat: Tuesday, December 3, 2024, at 1:20 p.m. EST in Coral Gables, Florida
- Foghorn Presenter: Adrian Gottschalk, President and Chief Executive Officer
- Please find a link to the webcast here
- Management will also participate in one-on-one meetings on Tuesday, December 3
Citi Global Healthcare Conference
- Management will participate in one-on-one meetings on Wednesday, December 4 in Miami, Florida
A webcast of both fireside chats can be accessed under “Events & Presentations” in the Investors section of the Company’s website, www.foghorntx.com, and will be available for 30 days.
About Foghorn Therapeutics
Foghorn® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control® platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The Company is developing multiple product candidates in oncology. Visit our website at www.foghorntx.com for more information on the Company, and follow us on X (formerly Twitter) and LinkedIn.
Contact:
Karin Hellsvik, Foghorn Therapeutics Inc.
khellsvik@foghorntx.com
FAQ
When is Foghorn Therapeutics (FHTX) presenting at the Jefferies London Healthcare Conference 2024?
Which conferences is Foghorn Therapeutics (FHTX) attending in late 2024?
Where can I watch Foghorn Therapeutics (FHTX) conference presentations?